Smoking and Cancer

Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies

Frits HM van Osch,[1,2]* Sylvia HJ Jochems,[1,2]
Frederik-Jan van Schooten,[3] Richard T Bryan[2] and
Maurice P Zeegers[1,2,4]

[1]Department of Complex Genetics, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands, [2]Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK, [3]Department of Pharmacology and Toxicology, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands and [4]Department of Complex Genetics, CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands.

*Corresponding author. Frits H.M. van Osch, Department of Complex Genetics, PO Box 616, 6200 MD Maastricht, The Netherlands. E-mail: f.vanosch@maastrichtuniversity.nl

Abstract

Background: Smoking is a major risk factor for bladder cancer (BC). This meta-analysis updates previous reviews on smoking characteristics and BC risk, and provides a more quantitative estimation of the dose-response relationship between smoking characteristics and BC risk.

Methods: In total, 89 studies comprising data from 57 145 BC cases were included and summary odds ratios (SORs) were calculated. Dose-response meta-analyses modelled relationships between smoking intensity, duration, pack-years and cessation and BC risk. Sources of heterogeneity were explored and sensitivity analyses were conducted to test the robustness of findings.

Results: Current smokers (SOR = 3.14, 95% CI = 2.53–3.75) and former smokers(SOR = 1.83, 95% CI = 1.52–2.14) had an increased risk of BC compared with never smokers. Age at first exposure was negatively associated with BC risk. BC risk increased gradually by smoking duration and a risk plateau at smoking 15 cigarettes a day and 50 pack-years was observed. Smoking cessation is most beneficial from 20 years before diagnosis. The population-attributable risk of BC for smokers has decreased from 50% to 43% in men and from 35% to 26% in women from Europe since estimated in 2000. Results were homogeneous between sources of heterogeneity, except for lower risk estimates found in studies of Asian populations.

Conclusions: Active smokers are at an increased risk of BC. Dose-response meta-analyses showed a BC risk plateau for smoking intensity and indicate that even after long-term smoking cessation, an elevated risk of bladder cancer remains.

857

Key Messages

- This large meta-analysis confirms smoking as a major risk factor for bladder cancer.
- A risk plateau is observed at smoking 15 cigarettes a day, and a 50% increased bladder cancer risk remains after long-term smoking cessation.
- The population-attributable risk of bladder cancer for smoking has decreased in Europe since 2000 because of a smaller number of smokers population-wide

Background

Bladder cancer (BC) is estimated to be the ninth most incident cancer worldwide, with around 400 000 new cases per year; the disease accounts for a larger share of total cancer incidence in more developed regions.[1] Cigarette smoking is a major risk factor for urothelial cell carcinoma (which also includes cancers of the renal pelvis and ureter).[2] Since recent studies estimated 22.8% of Europeans,[3] 18.1 % of North Americans[4] and 52.9% of males from China[5] smoke, it is expected to remain an important BC risk factor in the near future. Studies investigating the association between smoking and BC risk were summarized in a meta-analysis 15 years ago[2] and several systematic reviews.[6–8] However, further relevant studies have emerged since these reviews, allowing for more robust estimates, more detailed subgroup analyses and quantification of BC risk by dose-response investigations.

According to age- and gender-adjusted estimates from an earlier meta-analysis, those patients smoking at diagnosis (current smokers) had a 3.33-fold increased risk of developing BC compared with never smokers, and for former smokers the summary odds ratio (SOR) was 1.98; these age-adjusted risk estimates were comparable between males and females.[2] Furthermore, BC risk increased with the amount of cigarettes smoked per day and the number of years of smoking, although this was only assessed in a dichotomous way (e.g. 1–20 cigarettes per day vs >20 cigarettes per day) in this meta-analysis.[2]

The aim of this study was to provide an up-to-date estimation of the role of smoking in BC risk and to gain a more detailed quantification of several smoking characteristics (i.e. smoking intensity, duration and cessation) by performing dose-response meta-analyses.

Methods

Search strategy

Both Medline and Embase online databases were used to search for epidemiological studies on cigarette smoking and BC incidence. The search included the (MeSH) search terms 'urinary bladder neoplasms', 'incidence' 'risk', 'smoking' and 'epidemiologic studies' in different combinations, and resulted in a total count of 2112 articles after removal of duplicates. Publications were excluded if they did not involve humans. Publications that did not provide useable data to calculate risk estimates and the associated 95% confidence intervals for smoking characteristics and BC incidence were excluded. Included publications provided risk estimates for at least one of the selected cigarette smoking characteristics, including: smoking status (never, former, current), age at first exposure, daily cigarette consumption (intensity), duration of cigarette consumption, number of smoking pack-years and number of years since cessation. Publications reporting only on ever vs never smokers were excluded. Where a single study was described in several publications, the most recent publication was used for analysis.

Data collection

The Newcastle-Ottowa Scale (NOS) scale[9] was used to assess study quality and to extract information on possible sources of heterogeneity within individual publications by two of the authors (F.v.O. and S.J.). Information on the following variables was extracted and numerated in a dataset: year of publication, country and geographical area (North America, Europe, Asia, Africa, South America), anatomical site (bladder, upper tract urothelium, renal pelvis), cigarette smoking assessment (interview or questionnaire), case and control source (hospital, population or both) and factors adjusted for in the analysis. The association between smoking and BC risk is expressed in odds ratios (ORs) for both case-control studies and cohort studies included in this review. Where possible, risk estimate data were extracted directly from included articles and included both unadjusted and adjusted estimates. When direct risk estimates were not available, two-way

contingency tables were constructed separately and un-adjusted ORs and 95% confidence intervals were calculated. Since age and gender are considered to be major confounders of the association between smoking and BC, all included adjusted risk estimates adjusted for at least age and gender. For smoking duration, intensity, pack-years and cessation, risk estimates for smoking and BC risk were recorded per category, for example per 10 years of smoking duration, when data were available. Publications were excluded if the number of cases and/or controls or the number of person-years was not given.

Statistical analysis

In order to investigate publication bias, funnel plots were constructed, plotting the logarithmically transformed ORs against the standard error of the associated log (OR).[10]. The distribution of study risk estimates across the funnel plot was examined visually and Egger's test for small study effects was performed to assess the degree of asymmetry.[10] A random effects model was employed in all meta-analysis procedures. Between-study variance was estimated by I^2 and subgroup analyses. Stata statistical software was used for all analyses (version 13; Stata Corp., College Station, TX).

Summary ORs were estimated using classical meta-analysis for smoking status, age at first exposure (>20 years vs ≤20 years) and these results were obtained separately for men and women if data were available from the included publications. A cumulative meta-analysis was performed in order to investigate whether the association between smoking and BC incidence varied in time. Subgroup analyses were performed to explore differences in risk estimates between possible sources of heterogeneity, including geographical area, anatomical site, case and control source, study design and smoking assessment. The association of smoking duration, intensity, pack-years and cessation with BC risk was examined using a dose-response meta-analysis. The assigned dose for the dose-response analysis was determined by taking the median of each category (e.g. 15 cigarettes for category 10–20 cigarettes per day). Dose-response trends were estimated using both the variance-weighted least squares (VWLS) and generalized least squares (GLS) regression methods.[11] Since GLS is the most robust method with regard to inevitable covariance between study observations in a meta-analysis, the results from the GLS method are presented. Restricted cubic splines, which set knots at the 5th, 35th, 65th and 95th percentile, were used to investigate statistical non-linearity for all curves. Finally, population-attributable risk (PAR) of BC for current smokers compared with never smokers was estimated for Europe, North America and China, using the overall pooled risk estimates obtained by all included studies and the most


Figure 1. Flowchart of study selection and exclusion criteria.

recent estimates of proportions of smokers in these populations.

Results

Study characteristics

For this meta-analysis, 99 articles that discussed cigarette smoking and BC incidence were identified between 1968 and 2015, based on their abstract. After full-text evaluation, 89 articles were included for full analysis (Figure 1). Study characteristics including year of publication, country, case/control source, smoking assessment and anatomical site are summarized in Table 1. Six articles were excluded after full-text evaluation due to insufficient NOS score, duplicate populations in several articles or not being published in English.[101–106] Furthermore, three articles only presented data on ever smokers, as opposed to current and former smokers[107–109] and one cohort study did not present 95% confidence intervals and omitted the case-control data to calculate these.[110]

Of the 89 included studies, 72 were case-control studies[12–27,29,30,32–38,40–42,44–49,51,53–65,68,70–73,76,77,79,81–87,89,90,92,93,95–99] and 17 were cohort studies.[28,31,39,43,50,52,66,67,69,74,75,78,80,88,91,94,100] Three articles presented risk estimates from different study populations and were considered as separate studies in the analysis.[9,78,84] In the case-control studies, cases were identified from hospitals (*n* = 46)[13–15,17–23,26,29,33–38,40,41,46,49,53,54,57,58,64,65,70–73,76,77,81,83,85,86,89,90,93,96–99] or in predefined populations (*n* = 24),[16,24,25,27,32,35,42,47,48,55,56,59–63,68,79,82,84,87,92,95] and two studies used both hospital- and population-based cases;[12,30] 39 of the case-control studies recruited controls from hospitals[12–14,16,17,19,21–24,26,29,33–37,40,41,44–46,49,50,53,54,57,58,63–65,68,70,71,73,74,76–79,81–83,85–87,89,91–93,96,97,99] and 33 case-control studies recruited population controls.[15,18,20,25,27,30,32,35,38,42,45,47,48,51,52,55–57,59,61–63,68,70,72,79,82,84,87,90,92,95,98] Detailed information on cigarette smoking habits was assessed by interview (*n* = 62),[12–18,21,23,25–27,29,30,32–38,40,46,48,49,51,53,55,58,59,61,62,64,65,70,72,73,77,79,81–87,89,90,92,93,95–99] questionnaire, (*n* = 26),[19,20,24,28,31,39,47,52,56,57,60,63,66–69,71,74–76,78,80,88,91,94,100] and medical records (*n* = 1).[50]

Publication bias and heterogeneity

Some publication bias seemed to be present, as judged from funnel plots for current smoking risk estimates in studies that present unadjusted ORs (*n* = 45). Publication bias seemed to be of less importance in studies presenting age- and sex-adjusted (*n* = 11) and multiple-adjusted (*n* = 13) ORs. Egger's test for small study effects demonstrated that no small studies remained unpublished (*P* = 0.150). Judging from I² statistics, there may have been heterogeneity (most I² values between 70% and 90% for both classical- and dose-response meta-analyses); however, when assessing heterogeneity in subgroup analyses (Figure 2), there did not seem to be any substantial heterogeneity.

Risk estimates from classical meta-analysis

Table 2 summarizes both unadjusted and adjusted estimates for smoking status and age at first exposure obtained from the classical meta-analysis. The adjusted SOR for current smokers compared with never smokers was 3.14 (95% CI, 2.53–3.75). Former smokers had a 1.78 (95% CI, 1.53–2.03)-fold increased risk of developing BC compared with never smokers. This association was comparable between men (3.44, 95% CI, 2.67–4.22) and women (3.56, 95% CI, 2.76–4.36). When investigating all obtained estimates, the observed SORs remained comparable to the adjusted estimates.

For age at first exposure, five male-only studies presenting age-adjusted risk estimates were pooled, which resulted in an SOR of 1.36 (95% CI, 0.91–1.80) comparing males who started smoking before the age of 20 with those who had started smoking after the age of 20. Unadjusted SORs showed no effect of age at first exposure in females (0.99, 95% CI, 0.31–1.68) as opposed to stronger associations for males only (1.34, 95% CI, 1.02–1.68) and studies including both sexes (1.30, 95% CI, 1.13–1.47).

Risk estimates from dose-response meta-analysis

Dose-response curves estimated from studies reporting on smoking intensity (*n* = 23),[25,30,33–35,37–40,45–48,57,62,67,71,78,81,82,92,99] pack-years (*n* = 8),[34,50,61,71–73,82,94] duration (*n* = 15)[25,30,38,39,47,53,59,62,67,71,75,82,92,96,99] and cessation (*n* = 7)[25,33,38,67,72,92,94] and BC risk are depicted in Figure 3. The shape of both the intensity and pack-years curves is reminiscent of a logarithmic curve, showing a rapid increase of BC risk before declining at a certain point. For intensity, BC risk increases only marginally from smoking more than 15 cigarettes a day, and likewise for pack-years from 50 pack-years onwards. The risk of BC increases almost linearly by smoking duration in years, although statistical tests for non-linearity showed that it is non-linear (*P* < 0.05 at all investigated knots). Those who stopped smoking more than 25 years before diagnosis were at an approximately 1.5-fold higher risk of BC compared with never smokers, whereas those who stopped smoking between 5 and 15 years before diagnosis were at a 2-3-fold increased risk of BC compared with never smokers. There is a slight stagnation around 10 years of cessation, indicating a relatively small risk reduction between 5 and 15 years of smoking cessation.

Table 1. Study characteristics of included epidemiological studies with data on cigarette smoking and urothelial cell carcinoma, ordered by year of publication

| | | | | | | Study design | | | |
| | | | | | | | Case-control study | | |
Reference	First Author	Year	Country	Cases (*n*)	Anatomical site	Cohort study	Case source	Control source	Cigarette smoking assessment
(12)	Dunham	1968	USA	702	Bladder	–	Both	Hospital	Interview
(13)	Anthony	1970	UK	381	Bladder	–	Hospital	Hospital	Interview
(14)	Armstrong	1976	UK	33	Renal pelvis	–	Hospital	Hospital	Interview
(15)	Miller	1977	Canada	480	Bladder	–	Hospital	Population	Interview
(16)	Wynder	1977	USA	574	Bladder	–	Population	Hospital	Interview
(17)	Vineis	1981	Italy	225	Bladder	–	Hospital	Hospital	Interview
(18)	Morrison	1984	USA	1435	Urinary tract	–	Hospital	Population	Interview
(19)	Rebekalos	1985	Greece	300	Bladder	–	Hospital	Hospital	Questionnaire
(20)	Sandler	1985	USA	518	Bladder	–	Hospital	Population	Questionnaire
(21)	Vineis	1985	Italy	55	Bladder	–	Hospital	Hospital	Interview
(22)	Wynder	1985	USA	194	Bladder	–	Hospital	Hospital	Interview
(23)	Claude	1986	Germany	431	Bladder	–	Hospital	Hospital	Interview
(24)	Brownson	1987	USA	823	Bladder	–	Population	Hospital	Questionnaire
(25)	Hartge	1987	USA	2982	Bladder	–	Population	Population	Interview
(26)	Augustine	1988	USA	1821	Bladder	–	Hospital	Hospital	Interview
(27)	Slattery	1988	USA	332	Bladder	–	Population	Population	Interview
(28)	Steineck	1988	Swedish	70	Urinary tract	Yes	–	–	Questionnaire
(29)	Vineis	1988	Italy	567	Bladder	–	Hospital	Hospital	Interview
(30)	Burch	1989	Canada	826	Bladder	–	Both	Population	Interview
(31)	Helzlsouer	1989	USA	35	Bladder	Yes	–	–	Questionnaire
(32)	Ross	1989	USA	187	Urothelial	–	Population	Population	Interview
(33)	D'Avanzo	1990	Italy	337	Bladder	–	Hospital	Hospital	Interview
(34)	Harris	1990	USA	1663	Bladder	–	Hospital	Hospital	Interview
(35)	Hartge	1990	USA	2806	Bladder	–	Population	Population	Interview
(36)	De Stefani	1991	Uruguay	111	Bladder	–	Hospital	Hospital	Interview
(37)	La Vecchia	1991	Italy	364	Bladder	–	Hospital	Hospital	Interview
(38)	Lopez-Abente	1991	Spain	430	Bladder	–	Hospital	Population	Interview
(39)	Mills	1991	USA	52	Bladder	Yes	–	–	Questionnaire
(40)	D'Avanzo	1992	Italy	555	Bladder	–	Hospital	Hospital	Interview
(41)	Kunze	1992	Germany	675	Urinary tract	–	Hospital	Hospital	Interview
(42)	McLaughlin	1992	USA	502	Urothelial	–	Population	Population	Interview
(43)	Chyou	1993	Hawaii	96	Urinary tract	Yes	–	–	Interview
(44)	Cordier	1993	France	765	Bladder	–	Hospital	Hospital	Interview
(45)	Hayes	1993	USA	470	Urinary tract	–	Hospital	Population	Interview
(46)	Barbone	1994	Italy	273	Bladder	–	Hospital	Hospital	Interview
(47)	Sorahan	1994	UK	989	Bladder	–	Population	Population	Questionnaire
(48)	Sturgeon	1994	USA	1860	Bladder	–	Population	Population	Interview
(49)	D'Avanzo	1995	Italy	431	Bladder	–	Hospital	Hospital	Interview
(50)	Tremblay	1995	Canada	138	Bladder	Yes	–	–	Medical files
(51)	Bruemmer	1996	USA	262	Bladder	–	Population	Population	Interview
(52)	Engeland	1996	Norway	307	Urinary tract	Yes	–	–	Questionnaire
(53)	Bedwani	1997	Egypt	151	Bladder	–	Hospital	Hospital	Interview
(54)	Donato	1997	Italy	172	Bladder	–	Hospital	Hospital	Interview
(55)	Teschke	1997	Canada	105	Bladder	–	Population	Population	Interview
(56)	Koivusalo	1998	Finland	732	Bladder	–	Population	Population	Questionnaire
(57)	Sorahan	1998	UK	803	Urinary tract	–	Hospital	Population	Questionnaire
(58)	Pohlabeln	1999	Germany	300	Urinary tract	–	Hospital	Hospital	Interview

(continued)

Table 1. Continued

| Reference	First Author	Year	Country	Cases (*n*)	Anatomical site	Cohort study	Case-control study		Cigarette smoking assessment
							Case source	Control source	
(59)	Pommer	1999	Germany	571	Urothelial	–	Population	Population	Interview
(60)	Pesch	2000	Germany	1452	Urothelial	–	Population	Population	Questionnaire
(61)	Serra	2000	Spain	1035	Bladder	–	Population	Population	Interview
(62)	Castelao	2001	USA	218	Bladder	–	Population	Population	Interview
(63)	Chiu	2001	USA	1514	Bladder	–	Population	Population	Questionnaire
(64)	Vineis	2001	Europe	1530	Bladder	–	Hospital	Hospital	Interview
(65)	Pelluchi	2002	Italy	110	Bladder	–	Hospital	Hospital	Interview
(66)	Tripathi	2002	USA	112	Bladder	Yes	–	–	Questionnaire
(67)	Zeegers	2002	Netherlands	619	Bladder	Yes	–	–	Questionnaire
(68)	Gaertner	2004	Canada	887	Bladder	–	Population	Population	Questionnaire
(69)	Jee	2004	Korea	175	Bladder	Yes	–	–	Questionnaire
(70)	Karagas	2004	USA	383	Bladder	–	Hospital	Population	Interview
(71)	Quirk	2004	USA	499	Bladder	–	Hospital	Hospital	Questionnaire
(72)	Cao	2005	USA	145	Bladder	–	Hospital	Population	Interview
(73)	Chen	2005	Taiwan	41	Bladder	–	Hospital	Hospital	Interview
(74)	Bjerregaard	2006	Europe	633	Bladder	Yes	–	–	Questionnaire
(75)	Cantwell	2006	USA	167	Bladder	Yes	–	–	Questionnaire
(76)	Samanic	2006	Spain	1219	Bladder	–	Hospital	Hospital	Questionnaire
(77)	Terry	2006	USA	239	Bladder	–	Hospital	Hospital	Interview
(78)	Alberg	2007	USA	172	Bladder	Yes	–	–	Questionnaire
(79)	Jiang	2007	USA	148	Bladder	–	Population	Population	Interview
(80)	McGrath	2007	USA	184	Bladder	Yes	–	–	Questionnaire
(81)	Demirel	2008	Turkey	164	Bladder	–	Hospital	Hospital	Interview
(82)	Baris	2009	USA	1170	Bladder	–	Population	Population	Interview
(83)	Cassidy	2009	USA	604	Bladder	–	Hospital	Hospital	Interview
(84)	Stern	2009	China	1042	Bladder	–	Population	Population	Interview
(85)	Wen	2009	China	94	Bladder	–	Hospital	Hospital	Interview
(86)	Srivastava	2010	India	200	Bladder	–	Hospital	Hospital	Interview
(87)	Tao	2010	China	195	Bladder	–	Population	Population	Interview
(88)	Freedman	2011	USA	4523	Bladder	Yes	–	–	Questionnaire
(89)	Gangwar	2011	India	212	Bladder	–	Hospital	Hospital	Interview
(90)	MacKenzie	2011	UK	331	Bladder	–	Hospital	Population	Interview
(91)	Grant	2012	Japan	573	Urothelial	Yes	–	–	Questionnaire
(92)	Jiang	2012	USA	1586	Bladder	–	Population	Population	Interview
(93)	Liu	2012	China	600	Bladder	–	Hospital	Hospital	Interview
(94)	Welty	2012	USA	378	Bladder	Yes	–	–	Questionnaire
(95)	Ferreccio	2013	Chile	232	Bladder	–	Population	Population	Interview
(96)	Isa	2013	China	487	Bladder	–	Hospital	Hospital	Interview
(97)	Matic	2013	Serbia	201	Bladder	–	Hospital	Hospital	Interview
(98)	Amr	2014	Egypt	1840	Bladder	–	Hospital	Population	Interview
(99)	Polesel	2014	Italy	531	Bladder	–	Hospital	Hospital	Interview
(100)	Vermeulen	2014	Netherlands	1809	Bladder	Yes	–	–	Questionnaire

Figure 2. Forest plot depicting crude summary odds ratios (SOR) for current smokers vs non-smokers, by several possible sources of heterogeneity. The dashed line represents no effect and the solid line stands for the overall crude SOR of 2.96.

Table 2. Unadjusted and adjusted summary odds ratios for smoking status, age at first exposure and exposure to environmental tobacco smoke

	Male[a]				Female[a]				Male and female[b]			
Determinants, all investigated estimates	*n* studies	*n* cases	SOR	95% CI	*n* studies	n cases	SOR	95% CI	*n* studies	*n* cases	SOR	95% CI
Smoking status												
Non-smoker			1.00	Reference			1.00	Reference			1.00	Reference
Former smoker	26	25812	2.00	1.79, 2.21	24	24156	1.65	1.38, 1.93	63	40015	1.90	1.78, 2.03
Current smoker	30	28280	3.30	2.90, 3.70	29	26924	3.10	2.61, 3.58	69	43640	2.96	2.67, 3.25
Age at first exposure (years)												
<20			1.00	Reference			1.00	Reference			1.00	Reference
≥20	7	3619	1.34	1.02, 1.68	4	1856	0.99	0.31, 1.68	10	7556	1.30	1.13, 1.47
Determinants, only adjusted estimates												
Smoking status												
Non-smoker			1.00	Reference			1.00	Reference			1.00	Reference
Former smoker	10	11165	1.92	1.57, 2.27	9	9809	2.04	1.66, 2.42	12	8659	1.83	1.52, 2.14
Current smoker	11	11596	3.44	2.67, 4.22	10	10240	3.56	2.76, 4.36	13	9129	3.14	2.53, 3.75
Age at first exposure (years)												
<20			1.00	Reference			1.00	Reference			1.00	Reference
≥20	5	2493	1.36	0.91, 1.80	1	675	–	–	4	4320	1.33	0.92, 1.74

[a]Adjusted SORs are based on age-adjusted estimates.
[b]Adjusted SORs are based on (at least) age- and sex-adjusted estimates.

Sensitivity analyses

Subgroup analyses investigating the risk of BC of current smokers vs never smokers were performed to check for the influence of potential sources of heterogeneity (Figure 2). Most subgroup estimates seemed to be consistent with each other and did not indicate heterogeneity. However, the SOR of 1.91 (95% CI, 1.65–2.17) for the seven included Asian studies was lower compared with both European ($n = 25$, $P = 3.93 \times 10^{-7}$) and North-American ($n = 34$, $P = 4.40 \times 10^{-6}$) estimates. Of these seven studies (including 2760 cases), four investigated Chinese populations,

Figure 3. Dose-response curves as estimated by dose-response meta-analysis for smoking intensity (a), pack-years (b), duration (c) and years of smoking cessation (d). ORs indicating bladder cancer risk are listed on the y-axis and units of smoking are given on the x-axis. Never smokers are the reference category for all calculated ORs.

84,85,93,96 two investigated Japanese populations[18,91] and there was one prospective study in a Korean population[69] to estimate the effect of smoking on BC risk. Across these seven studies, estimates consistently indicated a 2-fold increase of BC risk as opposed to the overall (and European and North-American) estimate of a 3-fold increased risk of BC for current smokers compared with never smokers.

A cumulative meta-analysis, performed to check whether the risk estimate of BC for current smokers compared with never smokers changed over time since (included publications appeared in print between 1968 and 2015) indicated that there was a slight increase of BC risk for current smokers vs never smokers over time (Supplementary Figure 1, available as Supplementary data at *IJE* online). However, when only considering multiple adjusted (at least adjusted for age and sex) estimates, there were no changes in estimated risk of BC.

In addition to the presented dose-response curves estimated by GLS regression using restricted cubic splines, other methods (VWLS, linear regression) did not show different results when compared with GLS with regard to the estimated regression slope for all investigated smoking characteristics. Furthermore, the shape of the dose-response curves did not change substantially by varying with positioning of knots using the cubic splines method or when applying a fractional polynomials approach for curve estimation.

Population-attributable risks

In Europe approximately 28% of males and 18% of females smoke,[3] whereas in the USA these figures are estimated to be 21% and 16%.[4] By combining these figures with the pooled risk estimates per continent from this meta-analysis, PARs were calculated (Table 3). The fraction of BC cases attributable to cigarette smoking is 43% for males and 26% for females in Europe and 34% for males and 30% for females in the USA. Unfortunately, no studies presenting gender-specific ORs were found for the Chinese population; however, the PAR in the whole population seems smaller (20%) compared with both Europe and the USA, although the prevalence of smoking is larger in China.[5]

Discussion

This meta-analysis summarizes the findings of 89 observational studies, encompassing a total of 57 145 BC cases,

Table 3. Population-attributable risk (PAR) of bladder cancer according to exposure to cigarette smoking in North America, Europe and China

	No. of studies	SOR	Pe (smoking)	PAR
Men and women				
North America[b]	13	3.08	0.18	27%
Europe	9	3.62	0.23	37%
China	4	1.87	0.28	20%
Men only				
North America[a]	8	3.55	0.21	34%
Europe[c]	13	3.67	0.28	43%
China	0	–	0.53	–
Women only				
North America[a]	8	3.72	0.16	30%
Europe[c]	13	2.92	0.18	26%
China	0	–	0.02	–

Pe, prevalence of exposure (smoking).
[a]Based on age- and sex-adjusted estimates only.
[b]Based on unadjusted estimates only.
[c]Based on both adjusted and unadjusted estimates.

investigating the association between cigarette smoking and BC risk.

Smoking status and age at first exposure influence BC risk

Our findings support earlier reviews in indicating an increased risk of BC for cigarette smokers. Age at first exposure is negatively associated with BC risk; however, no studies adjusted for smoking duration or smoking intensity as possible effect modifiers in the included publications.

Dose-response relationship between smoking intensity and BC risk, with a risk plateau at 15 cigarettes a day

Increasing smoking intensity (i.e. smoking more cigarettes per day) seems to be of less additional impact on BC risk when smoking more than 15 cigarettes a day. Perhaps surprisingly, very heavy smokers (e.g. 50 cigarettes a day) do not experience a markedly increased risk compared with less heavy smokers. A similar relationship is observed for pack-years, but with a risk plateau at approximately 50 pack-years. These results are in line with experimental and molecular epidemiological studies in which saturation is observed of smoking-related DNA adduct levels in lymphocytes and lung cells at higher doses, leading to non-linear dose-response relationships.[111] In the bladders of mice treated with the bladder carcinogen 4-aminobiphenyl (4-ABP), adduct levels in bladder DNA and associated bladder tumours increased by dose at low doses, but saturation was observed at high doses.[112] Similarly in smokers,

adduct levels (derived from the tobacco carcinogens polycyclic aromatic hydrocarbons and 4-ABP) in blood cells plateaued at 20 cigarettes per day,[113] which is in agreement with the presently observed dose-response relationship in BC risk. Although these studies might provide some biological explanation for the observed risk plateau, it is not replicated in other smoking-related cancers such as lung cancer,[114] where the association seems to be linear, or head-and neck cancer where some studies show a similar risk plateau[115] but others indicate a linear association.[116] Therefore, more research is needed on the possible mechanism that underlies the observed association between smoking intensity and BC risk.

Smoking cessation is most beneficial more than 20 years before diagnosis, but still causes a long-term BC risk increase

Many smokers believe that smoking cessation will cause their risk of several diseases to return to the risk of a non-smoker over a very short period.[117] However, this analysis unambiguously shows that lowering BC risk after smoking cessation takes time. The beneficial effect of smoking cessation on BC risk is largest when having stopped smoking more than 20 years before diagnosis. Even then, the risk of former smokers does not return to the risk of non-smokers. Even after 20 years of cessation, ex-smokers remain at a 50% increased risk compared with those who have never smoked. Furthermore, there does not seem to be a substantial risk reduction between 5 and 15 years of smoking cessation before diagnosis. Although smoking cessation seems to be the only efficient mechanism to counteract smoking-induced pathogenic processes leading to cancer,[118] these results show that the malignant effects of exposure to tobacco-related carcinogens can linger for a lifetime in the bladder. The risk of BC per year of smoking increases gradually every year, indicating that smoking cessation programmes should aim to achieve smoking cessation as early in life as possible to effectively decrease BC risk due to smoking. The presented dose-response curves might be useful aids for developing such smoking cessation strategies.

Lower risk of BC for smokers in Asian compared with Caucasian populations

All studies in Asian populations observed lower ORs compared with pooled estimates from Europe and the USA. A similar difference was observed in lung cancer, where a meta-analysis showed a markedly lower pooled risk ratio (RR) for smokers compared with never-smokers in Asian populations (pooled RR = 5.52, 95% CI, 2.83–10.78) compared with studies in Caucasian populations (pooled

RR = 9.94, 95% CI, 5.92, 16.67).[119] Even though the exact mechanism behind this lower susceptibility for tobacco-related cancers in Asian populations remains unclear, there is some evidence that nicotine intake from cigarette smoking is lower and that therefore Asian populations might be less susceptible to the harmful effects of tobacco smoke compared with Caucasian populations.[120]

Decreased population-attributable risk (PAR) in Western countries for cigarette smoking in BC

The PAR calculated for Europe was noticeably lower compared with the estimated PAR from the 2000 meta-analysis,[2] where it was estimated that 50% of male cases and 35% of female cases were attributable to smoking, as opposed to the 43% and 26% for men and women, respectively, which were estimated in the current meta-analysis. This indicates that the burden of smoking on bladder cancer incidence has decreased. Although we have no earlier PAR estimate for the USA, it is likely that a similar decrease in BC risk attributable to smoking has occurred during the past 15 years. These lower figures,are due to the currently decreasing number of smokers in these populations,[3,4] since the risk of BC associated with smoking remains unaltered, as we show in our cumulative meta-analysis. Even though the PARs were lower, the total number of worldwide incident BC cases only slightly decreased from 356 557 in 2002[121] to 330 380 in 2012,[1] emphasizing the continuing importance of development of effective smoking cessation and prevention programmes. Interestingly, a pooled analysis from Nordic countries found very similar PARs (41% in males and 32% in females) to what we observed in 1997,[122] indicating that there might be meaningful differences in PAR even at a regional level. Unfortunately, no PAR has been calculated previously for Eastern countries, so we could not compare our estimated PAR for China with previous results. However, since smoking prevalence is still on the rise in China,[5] it is highly unlikely that the PAR has decreased over the past years in China or other Eastern countries.

Bias and heterogeneity

Although the number of included studies was large, many articles did not present adjusted risk estimates. Since there was a difference in pooled OR between studies showing adjusted estimates compared with unadjusted estimates, we expect that not adjusting for at least age and sex might lead to underestimation of the strength of the association between smoking and BC incidence, given the higher pooled OR for adjusted risk estimates.,In the dose-response meta-analysis, both adjusted and unadjusted risk

estimates were included and there was no heterogeneity between studies caused by the number of factors adjusted for.

In this meta-analysis, publication bias may have played a role since no attempts were made to include unpublished observations, and several studies were excluded because of not meeting the selection criteria. Additionally, when investigating funnel plots, the observed bias was bipolar (e.g. included both higher and lower estimates) and occurred mostly between larger studies. Since some degree of heterogeneity was likely to occur due to differences in study methodology (e.g. study population, design, smoking assessment) between the large number of studies included, a random effects approach to the meta-analyses was used. This approach allowed for more heterogeneity in studies beyond sampling error, as opposed to a fixed effects approach.[123]

Sensitivity analyses

Subgroup analyses showed that SORs were similar across several possible sources of heterogeneity, except for studies from Asian populations. A cumulative meta-analysis showed no time effect on the overall risk estimate of smoking for BC. Although several regression methods were used for dose-response curve estimation, there were no differences between the shapes of the estimated curves resulting from the different analyses. Also, varying the knots (which determine how the curves are estimated) did not cause major changes in the shape of the curves. Both of these observations lead to the conclusion that the presented GLS curves are robust and can be interpreted as such.

Study limitations

Because only 15 studies which adjusted for multiple factors (of which eight adjusted their BC risk estimates for smokers for factors other than age and sex) were included, the pooled estimates obtained are not completely free of possible confounding due to other factors influencing BC risk. The number of studies adjusting for multiple risk factors was probably low because especially the more recently published studies often do not focus solely on smoking but only consider smoking status as a stratifying factor in their molecular analyses for example. Nevertheless, apart from smoking, only occupational exposure to carcinogens has been identified as a major risk factor for BC. Since the frequency of occupational exposure is so long it is unlikely to be a confounder and therefore many individual studies may have not corrected for this. In addition, studies included in this meta-analysis did not include sufficient data to stratify for important molecular aberrations which play a role in BC development. Studies on molecular

determinants of BC development have unveiled *TP53* mutation and chromosome 9 defects as frequent molecular aberrations in BC aetiology.[124,125] Also, glutathione S-transferase M1 (GSTM1) and N-acetyl transferase2 (NAT2) deficiencies are both associated with increased bladder cancer risk and are together estimated to account for about 30% of bladder cancer cases in Caucasian populations.[126] Recently, several single nucleotide polymorphisms (SNPs) associated with increased risk of BC have been identified on candidate genes such as fibroblast growth factor receptor 3 (FGFR3) and telomerase reverse transcriptase (TERT).[127] Some case-control studies focusing on molecular aberrations and BC also included data on smoking; however, almost all of the molecular studies found in our search did not present any useable smoking data for this meta-analysis.

Conclusion

Our findings are in line with results from earlier meta-analyses and reviews indicating an estimated 3-fold higher risk of BC for cigarette smokers. Age at first exposure was negatively associated with BC risk. The proportions of BC cases attributable to smoking (PARs) were noticeably lower than estimated in 2000 for both males and females, driven by the decreasing number of smokers in Western countries. Furthermore, we estimated dose-response curves providing a more graphic quantification of the impact of smoking intensity, pack-years, duration and cessation on BC risk, and these provide opportunities for development of smoking cessation and prevention programmes which should aim for smoking cessation at an early age.

Supplementary Data

Supplementary data are available at *IJE* online.

Conflict of interest: All authors certify that they have no affiliations with or involvement in any organisation or entity with any financial interest in the subject matter or materials discussed in this manuscript.

References

1. Ferlay J, Soerjomataram I, Dikshit R *et al*. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015;**136:**E359–86.
2. Zeegers M, Tan FE, Dorant E, van den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk. *Cancer* 2000;**89:**630–39.
3. Organisation for Economic Co-operation and Development (OECD). *Health at a Glance: Europe 2014*. OECD Publishing. 2014. http://dx.doi.org/10.1787/health_glance_eur-2014-en (October 2015, date last accessed).
4. Agaku IT, King BA, Dube SR; Centers for Disease Control and Prevention. Current cigarette smoking among adults—United States, 2005–2012. *MMWR Morb Mortal Wkly Rep* 2014; **63:**29–34.
5. Li Q, Hsia J, Yang G. Prevalence of smoking in China in 2010. *N Engl J Med* 2011;**364:**2469–70.
6. Letašiová S, Medve'Ova A, Šovčíková A *et al*. Bladder cancer, a review of the environmental risk factors. *Environ Health* 2012;**11(Suppl 1):**S11.
7. Zeegers MP, Kellen E, Buntinx F, van den Brandt PA. The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review. *World J Urol* 2004; **21:**392–401.
8. Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M; Comparative Risk Assessment Collaborating Group (Cancers). Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. *Lancet* 2005;**366:**1784–93.
9. Wells G, Shea B, O'Connell D. *The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses*. Ottawa, ON: Ottawa Hospital Research Institute, 2013.
10. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;**315:**629–34.
11. Orsini N, Li R, Wolk A, Khudyakov P, Spiegelman D. Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. *Am J Epidemiol* 2012;**175:**66–73.
12. Dunham LJ, Rabson AS, Stewart HL, Frank AS, Young JL. Rates, Interview, and pathology study of cancer of the urinary bladder in New Orleans, Louisiana. *J Natl Cancer Inst* 1968;**41:**683–709.
13. Anthony HM, Thomas GM. Bladder tumours and smoking. *Int J Cancer* 1970;**5:**266–72.
14. Armstrong B, Garrod A, Doll R. A retrospective study of renal cancer with special reference to coffee and animal protein consumption. *Br J Cancer* 1976;**33:**127–36.
15. Miller A, Howe G. Artificial sweeteners and bladder cancer. *Lancet* 1977;**310:**1221–22.
16. Wynder EL, Stellman SD. Comparative epidemiology of tobacco-related cancers. *Cancer Res* 1977;**37:**4608–22.
17. Vineis P, Segnan N, Costa G, Terracini B. Evidence of a multiplicative effect between cigarette smoking and occupational exposures in the aetiology of bladder cancer. *Cancer Lett* 1981; **14:**285–90.
18. Morrison AS, Buring JE, Verhoek WG *et al*. An international study of smoking and bladder cancer. *J Urol* 1984;**131:**650–54.
19. Rebelakos A, Trichopoulos D, Tzonou A, Zavitsanos X, Velonakis E, Trichopoulos A. Tobacco smoking, coffee drinking, and occupation as risk factors for bladder cancer in Greece. *J Natl Cancer Inst* 1985;**75:**455–61.
20. Sandler DP, Everson RB, Wilcox AJ. Passive smoking in adulthood and cancer risk. *Am J Epidemiol* 1985;**121:**37–48.
21. Vineis P, Ciccone G, Ghisetti V, Terracini B. Cigarette smoking and bladder cancer in females. *Cancer Lett* 1985;**26:**61–66.
22. Wynder EL, Dieck GS, Hall NE, Lahti H. A case-control study of diesel exhaust exposure and bladder cancer. *Environ Res* 1985;**37:**475–89.

23. Claude J, Kunze E, Frentzel-Beyme R, Paczkowski K, Schneider J, Schubert H. Life-style and occupational risk factors in cancer of the lower urinary tract. *Am J Epidemiol* 1986;**124**:578–89.

24. Brownson RC, Chang JC, Davis JR. Occupation, smoking, and alcohol in the epidemiology of bladder cancer. *Am J Public Health* 1987;**77**:1298–300.

25. Hartge P, Silverman D, Hoover R *et al*. Changing cigarette habits and bladder cancer risk: a case-control study. *J Natl Cancer Inst* 1987;**78**:1119–25.

26. Augustine A, Hebert JR, Kabat GC, Wynder EL. Bladder cancer in relation to cigarette smoking. *Cancer Res* 1988;**48**: 4405–08.

27. Slattery ML, Schumacher MC, West DW, Robison LM. Smoking and bladder cancer. The modifying effect of cigarettes on other factors. *Cancer* 1988;**61**:402–08.

28. Steineck G, Norell SE, Feychting M. Diet, tobacco and urothelial cancer. A 14-year follow-up of 16,477 subjects. *Acta Oncol* 1988;**27**:323–27.

29. Vineis P, Esteve J, Hartge P, Hoover R, Silverman DT, Terracini B. Effects of timing and type of tobacco in cigarette-induced bladder cancer. *Cancer Res* 1988;**48**:3849–52.

30. Burch J, Rohan T, Howe G *et al*. Risk of bladder cancer by source and type of tobacco exposure: A case-control study. *Int J Cancer* 1989;**44**:622–28.

31. Helzlsouer KJ, Comstock GW, Morris JS. Selenium, lycopene, alpha-tocopherol, beta-carotene, retinol, and subsequent bladder cancer. *Cancer Res* 1989;**49**:6144–48.

32. Ross RK, Paganini-Hill A, Landolph J, Gerkins V, Henderson BE. Analgesics, cigarette smoking, and other risk factors for cancer of the renal pelvis and ureter. *Cancer Res* 1989;**49**:1045–48.

33. D'Avanzo B, Negri E, La Vecchia C *et al*. Cigarette smoking and bladder cancer. *Eur J Cancer* 1990;**26**:714–18.

34. Harris RE, Chen-Backlund JY, Wynder EL. Cancer of the urinary bladder in blacks and whites. *A case-control study*. Cancer 1990;**66**:2673–80.

35. Hartge P, Harvey EB, Linehan WM *et al*. Unexplained excess risk of bladder cancer in men. *J Natl Cancer Inst* 1990;**82**:1636–40.

36. de Stefani E, Correa P, Fierro L, Fontham E, Chen V, Zavala D. Black tobacco, mate, and bladder cancer. A case–control study from Uruguay. *Cancer* 1991;**67**:536–40.

37. La Vecchia C, Negri E, D'Avanzo B, Savoldelli R, Franceschi S. Genital and urinary tract diseases and bladder cancer. *Cancer Res* 1991;**51**:629–31.

38. Lopez-Abente G, Gonzalez CA, Errezola M *et al*. Tobacco smoke inhalation pattern, tobacco type, and bladder cancer in Spain. *Am J Epidemiol* 1991;**134**:830–39.

39. Mills PK, Beeson WL, Phillips RL, Fraser GE. Bladder cancer in a low risk population: results from the Adventist Health Study. *Am J Epidemiol* 1991;**133**:230–39.

40. D'Avanzo B, La Vecchia C, Franceschi S, Negri E, Talamini R, Buttino I. Coffee consumption and bladder cancer risk. *Eur J Cancer* 1992;**28A**:1480–84.

41. Kunze E, Chang-Claude J, Frentzel-Beyrne R. Life style and occupational risk factors for bladder cancer in Germany. A case-control study. *Cancer* 1992;**69**:1776–90.

42. McLaughlin JK, Silverman DT, Hsing AW *et al*. Cigarette smoking and cancers of the renal pelvis and ureter. *Cancer Res* 1992;**52**:254–57.

43. Chyou P-H, Nomura AMY, Stemmermann GN. A prospective study of diet, smoking, and lower urinary tract cancer. *Ann Epidemiol* 1993;**3**:211–16.

44. Cordier S, Clavel J, Limasset JC *et al*. Occupational risks of bladder cancer in France: a multicentre case-control study. *Int J Epidemiol* 1993;**22**:403–11.

45. Hayes RB, Friedell GH, Zahm SH, Cole P. Are the known bladder cancer risk-factors associated with more advanced bladder cancer?. *Cancer Causes Control* 1993;**4**:157–62.

46. Barbone F, Franceschi S, Talamini R, Bidoli E, La Vecchia C. Occupation and bladder cancer in Pordenone (north-east Italy): a case-control study. *Int J Epidemiol* 1994;**23**:58–65.

47. Sorahan T, Lancashire RJ, Sole G. Urothelial cancer and cigarette smoking: findings from a regional case-controlled study. *Br J Urol* 1994;**74**:753–56.

48. Sturgeon SR, Hartge P, Silverman DT *et al*. Associations between bladder cancer risk factors and tumor stage and grade at diagnosis. *Epidemiology* 1994;**5**:218–25.

49. D'Avanzo B, La Vecchia C, Negri E, Decarli A, Benichou J. Attributable risks for bladder cancer in northern Italy. *Ann Epidemiol* 1995;**5**:427–31.

50. Tremblay C, Armstrong B, Theriault G, Brodeur J. Estimation of risk of developing bladder cancer among workers exposed to coal tar pitch volatiles in the primary aluminum industry. *Am J Ind Med* 1995;**27**:335–48.

51. Bruemmer B, White E, Vaughan TL, Cheney CL. Nutrient intake in relation to bladder cancer among middle-aged men and women. *Am J Epidemiol* 1996;**144**:485–95.

52. Engeland A, Andersen A, Haldorsen T, Tretli S. Smoking habits and risk of cancers other than lung cancer: 28 years' follow-up of 26 000 Norwegian men and women. *Cancer Causes Control* 1996;**7**:497–506.

53. Bedwani R, el-Khwsky F, Renganathan E *et al*. Epidemiology of bladder cancer in Alexandria, Egypt: tobacco smoking. *Int J Cancer* 1997;**73**:64–67.

54. Donato F, Boffetta P, Fazioli R, Aulenti V, Gelatti U, Porru S. Bladder cancer, tobacco smoking, coffee and alcohol drinking in Brescia, northern Italy. *Eur J Epidemiol* 1997;**13**:795–800.

55. Teschke K, Morgan MS, Checkoway H *et al*. Surveillance of nasal and bladder cancer to locate sources of exposure to occupational carcinogens. *Occup Environ Med* 1997;**54**:443–51.

56. Koivusalo M, Hakulinen T, Vartiainen T, Pukkala E, Jaakkola JJ, Tuomisto J. Drinking water mutagenicity and urinary tract cancers: a population-based case-control study in Finland. *Am J Epidemiol* 1998;**148**:704–12.

57. Sorahan T, Hamilton L, Wallace DM, Bathers S, Gardiner K, Harrington JM. Occupational urothelial tumours: a regional case-control study. *Br J Urol* 1998;**82**:25–32.

58. Pohlabeln H, Jockel KH, Bolm-Audorff U. Non-occupational risk factors for cancer of the lower urinary tract in Germany. *Eur J Epidemiol* 1999;**15**:411–19.

59. Pommer W, Bronder E, Klimpel A, Helmert U, Greiser E, Molzahn M. Urothelial cancer at different tumour sites: role of smoking and habitual intake of analgesics and laxatives.

Results of the Berlin Urothelial Cancer Study. *Nephrol Dial Transplant* 1999;**14**:2892–97.

60. Pesch B, Haerting J, Ranft U, Klimpel A, Oelschlagel B, Schill W. Occupational risk factors for urothelial carcinoma: agent-specific results from a case-control study in Germany. MURC Study Group. Multicenter Urothelial and Renal Cancer. *Int J Epidemiol* 2000;**29**:238–47.

61. Serra C, Bonfill X, Sunyer J *et al*. Bladder cancer in the textile industry. *Scand J Work Environ Health* 2000;**26**:476–81.

62. Castelao JE, Yuan J-M, Skipper PL *et al*. Gender-and smoking-related bladder cancer risk. *J Natl Cancer Inst* 2001;**93**:538–45.

63. Chiu BC, Lynch CF, Cerhan JR, Cantor KP. Cigarette smoking and risk of bladder, pancreas, kidney, and colorectal cancers in Iowa. *Ann Epidemiol* 2001;**11**:28–37.

64. Vineis P, Marinelli D, Autrup H *et al*. Current smoking, occupation, n-acetyltransferase-2 and bladder cancer: a pooled analysis of genotype-based studies. *Cancer Epidemiol Biomarkers Prev* 2001;**10**:1249–52.

65. Pelucchi C, La Vecchia C, Negri E, Dal Maso L, Franceschi S. Smoking and other risk factors for bladder cancer in women. *Prev Med* 2002;**35**:114–20.

66. Tripathi A, Folsom AR, Anderson KE. Risk factors for urinary bladder carcinoma in postmenopausal women. The Iowa Women's Health Study. *Cancer* 2002;**95**:2316–23.

67. Zeegers MP, Goldbohm RA, van den Brandt PA. A prospective study on active and environmental tobacco smoking and bladder cancer risk (The Netherlands). *Cancer Causes Control* 2002;**13**:83–90.

68. Gaertner RR, Trpeski L, Johnson KC. A case–control study of occupational risk factors for bladder cancer in Canada. *Cancer Causes Control* 2004;**15**:1007–19.

69. Jee SH, Samet JM, Ohrr H, Kim JH, Kim IS. Smoking and cancer risk in Korean men and women. *Cancer Causes Control* 2004;**15**:341–48.

70. Karagas MR, Tosteson TD, Morris JS *et al*. Incidence of transitional cell carcinoma of the bladder and arsenic exposure in New Hampshire. *Cancer Causes Control* 2004;**15**:465–72.

71. Quirk JT, Li Q, Natarajan N, Mettlin CJ, Cummings KM. Cigarette smoking and the risk of bladder cancer in men and women. *Tob Induc Dis* 2004;**2**:1–4.

72. Cao W, Cai L, Rao JY *et al*. Tobacco smoking, GSTP1 polymorphism, and bladder carcinoma. *Cancer* 2005;**104**:2400–08.

73. Chen Y-C, Su H-JJ, Guo Y-LL, Houseman EA, Christiani DC. Interaction between environmental tobacco smoke and arsenic methylation ability on the risk of bladder cancer. *Cancer Causes Control* 2005;**16**:75–81.

74. Bjerregaard BK, Raaschou-Nielsen O, Sørensen M *et al*. Tobacco smoke and bladder cancer—in the European Prospective Investigation into Cancer and Nutrition. *Int J Cancer* 2006;**119**:2412–16.

75. Cantwell MM, Lacey JV, Schairer C, Schatzkin A, Michaud DS. Reproductive factors, exogenous hormone use and bladder cancer risk in a prospective study. *Int J Cancer* 2006;**119**:2398–401.

76. Samanic C, Kogevinas M, Dosemeci M *et al*. Smoking and bladder cancer in Spain: effects of tobacco type, timing, environmental tobacco smoke, and gender. *Cancer Epidemiol Biomarkers Prev* 2006;**15**:1348–54.

77. Terry PD, Umbach DM, Taylor JA. APE1 genotype and risk of bladder cancer: evidence for effect modification by smoking. *Int J Cancer* 2006;**118**:3170–73.

78. Alberg AJ, Kouzis A, Genkinger JM *et al*. A prospective cohort study of bladder cancer risk in relation to active cigarette smoking and household exposure to secondhand cigarette smoke. *Am J Epidemiol* 2007;**165**:660–66.

79. Jiang X, Yuan J-M, Skipper PL, Tannenbaum SR, Mimi CY. Environmental tobacco smoke and bladder cancer risk in never smokers of Los Angeles County. *Cancer Res* 2007;**67**:7540–45.

80. McGrath M, Wong JY, Michaud D, Hunter DJ, De Vivo I. Telomere length, cigarette smoking, and bladder cancer risk in men and women. *Cancer Epidemiol Biomarkers Prev* 2007;**16**:815–19.

81. Demirel F, Cakan M, Yalçınkaya F, Topcuoglu M, Altug U. The association between personal habits and bladder cancer in Turkey. *Int Urol Nephrol* 2008;**40**:643–47.

82. Baris D, Karagas MR, Verrill C *et al*. A case-control study of smoking and bladder cancer risk: emergent patterns over time. *J Natl Cancer Inst* 2009;**101**:1553–61.

83. Cassidy A, Wang W, Wu X, Lin J. Risk of urinary bladder cancer: a case-control analysis of industry and occupation. *BMC Can* 2009;**9**:443.

84. Stern MC, Van Den Berg D, Yuan J-M *et al*. Sequence variant on 3q28 and urinary bladder cancer risk: findings from the Los Angeles-Shanghai bladder case-control study. *Cancer Epidemiol Biomarkers Prev* 2009;**18**:3057–61.

85. Wen H, Ding Q, Fang Z-j, Xia G-w, Fang J. Population study of genetic polymorphisms and superficial bladder cancer risk in Han-Chinese smokers in Shanghai. *Int Urol Nephrol* 2009;**41**:855–64.

86. Srivastava P, Gangwar R, Kapoor R, Mittal RD. Bladder cancer risk associated with genotypic polymorphism of the matrix metalloproteinase-1 and 7 in North Indian population. *Dis Markers* 2010;**29**:37–46.

87. Tao L, Xiang Y-B, Wang R *et al*. Environmental tobacco smoke in relation to bladder cancer risk—the Shanghai bladder cancer study. *Cancer Epidemiol Biomarkers Prev* 2010;**19**:3087–95.

88. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. *JAMA* 2011;**306**:737.

89. Gangwar R, Mandhani A, Mittal RD. Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for urinary bladder cancer in North India. *Surgery* 2011;**149**:126–34.

90. MacKenzie T, Zens MS, Ferrara A, Schned A, Karagas MR. Diabetes and risk of bladder cancer: evidence from a case-control study in New England. *Cancer* 2011;**117**:1552–56.

91. Grant EJ, Ozasa K, Preston D *et al*. Effects of radiation and lifestyle factors on risks of urothelial carcinoma in the life span study of atomic bomb survivors. *Radiat Res* 2012;**178**:86–98.

92. Jiang X, Castelao JE, Yuan JM *et al*. Cigarette smoking and subtypes of bladder cancer. *Int J Cancer* 2012;**130**:896–901.

93. Liu Y, Wang H, Lin T *et al*. Interactions between cigarette smoking and XPC-PAT genetic polymorphism enhance bladder cancer risk. *Oncol Rep* 2012;**28**:337–45.

94. Welty CJ, Wright JL, Hotaling JM, Bhatti P, Porter MP, White E. Persistence of urothelial carcinoma of the bladder risk

among former smokers: Results from a contemporary, prospective cohort study. *Urol Oncol* 2014;**32**:25.

95. Ferreccio C, Yuan Y, Calle J *et al*. Arsenic, tobacco smoke, and occupation: associations of multiple agents with lung and bladder cancer. *Epidemiology* 2013;**24**:898–905.

96. Isa F, Xie L-P, Hu Z *et al*. Dietary consumption and diet diversity and risk of developing bladder cancer: results from the South and East China case–control study. *Cancer Causes Control* 2013;**24**:885–95.

97. Matic M, Pekmezovic T, Djukic T *et al*. GSTA1, GSTM1, GSTP1, and GSTT1 polymorphisms and susceptibility to smoking-related bladder cancer: A case-control study. *Urol Oncol* 2013;**31**:1184–92.

98. Amr S, Dawson R, Saleh Da A *et al*. Agricultural workers and urinary bladder cancer risk in Egypt. *Arch Environ Health* 2014;**69**:3–10.

99. Polesel J, Bosetti C, di Maso M *et al*. Duration and intensity of tobacco smoking and the risk of papillary and non-papillary transitional cell carcinoma of the bladder. *Cancer Causes Control* 2014;**25**:1151–58.

100. Vermeulen S, Hanum N, Grotenhuis A *et al*. Recurrent urinary tract infection and risk of bladder cancer in the Nijmegen bladder cancer study. *Br J Cancer* 2015;**112**:594–600.

101. Baena AV, Allam MF, Del Castillo AS *et al*. Urinary bladder cancer risk factors in men: a Spanish case–control study. *Eur J Cancer Prev* 2006;**15**:498–503.

102. Sadetzki S, Bensal D, Blumstein T, Novikov I, Modan B. Selected risk factors for transitional cell bladder cancer. *Med Oncol* 2000;**17**:179–82.

103. Hours M, Dananche B, Fevotte J *et al*. Bladder cancer and occupational exposures. *Scand J Work Environ Health* 1994;**20**:322–30.

104. Jiang X, Castelao JE, Groshen S *et al*. Alcohol consumption and risk of bladder cancer in Los Angeles County. *Int J Cancer* 2007;**121**:839–45.

105. Hartge P, Hoover R, Kantor A. Bladder cancer risk and pipes, cigars, and smokeless tobacco. *Cancer* 1985;**55**:901–06.

106. Vineis P, Frea B, Uberti E, Ghisetti V, Terracini B. Bladder cancer and cigarette smoking in males: a case-control study. *Tumori* 1983;**69**:17–22.

107. Jensen OM, Wahrendorf J, Blettner M, Knudsen J, Sørensen B. The Copenhagen case-control study of bladder cancer: role of smoking in invasive and non-invasive bladder tumours. *J Epidemiol Community Health* 1987;**41**:30–36.

108. Lin J, Spitz MR, Dinney CP, Etzel CJ, Grossman HB, Wu X. Bladder cancer risk as modified by family history and smoking. *Cancer* 2006;**107**:705–11.

109. Wang Y-H, Yeh S-D, Wu M-M *et al*. Comparing the joint effect of arsenic exposure, cigarette smoking and risk genotypes of vascular endothelial growth factor on upper urinary tract urothelial carcinoma and bladder cancer. *J Hazard Mater* 2013;**262**:1139–46.

110. McCormack VA, Agudo A, Dahm CC *et al*. Cigar and pipe smoking and cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Int J Cancer* 2010;**127**:2402–11.

111. Godschalk RW, Van Schooten F-J, Bartsch H. A critical evaluation of DNA adducts as biological markers for human exposure to polycyclic aromatic compounds. *Biochem Mol Biol Int* 2003;**36**:1–11.

112. Poirier MC, Fullerton NF, Smith BA, Beland FA. DNA adduct formation and tumorigenesis in mice during the chronic administration of 4-aminobiphenyl at multiple dose levels. *Carcinogenesis* 1995;**16**:2917–21.

113. Dallinga JW, Pachen D, Wijnhoven S, *et al*. The use of 4-aminobiphenyl hemoglobin adducts and aromatic DNA adducts in lymphocytes of smokers as biomarkers of exposure. *Cancer Epidemiol Biomarkers Prev* 1998;**7**:571–77.

114. Lee PN, Forey BA, Coombs KJ. Systematic review with meta-analysis of the epidemiological evidence in the 1900s relating smoking to lung cancer. *BMC Can* 2012;**12**:385.

115. Wyss A, Hashibe M, Chuang S-C *et al*. Cigarette, cigar, and pipe smoking and the risk of head and neck cancers: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. *Am J Epidemiol* 2013;**178**:679–90.

116. Maasland DH, van den Brandt PA, Kremer B, Goldbohm RAS, Schouten LJ. Alcohol consumption, cigarette smoking and the risk of subtypes of head-neck cancer: results from the Netherlands Cohort Study. *BMC Can* 2014;**14**:187.

117. De Vries H, Mudde AN, Dijkstra A, Willemsen MC. Differential beliefs, perceived social influences, and self-efficacy expectations among smokers in various motivational phases. *Prev Med* 1998;**27**:681–89.

118. Department of Health and Human Services US. *How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-attributable Disease*. Washington, DC: Centers for Disease Control and Prevention, 2010.

119. Gandini S, Botteri E, Iodice S *et al*. Tobacco smoking and cancer: A meta-analysis. *Int J Cancer* 2008;**122**:155–64.

120. Benowitz NL, Pérez-Stable EJ, Herrera B, Jacob P. Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans. *J Natl Cancer Inst* 2002;**94**:108–15.

121. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer* 2005;**55**:74–108.

122. Dreyer L, Winther J, Pukkala E, Andersen A. Tobacco smoking. *APMIS* 1997;**105**:9–47.

123. Hedges LV, Vevea JL. Fixed-and random-effects models in meta-analysis. *Psychol Methods* 1998;**3**:486.

124. Hartmann A, Schlake G, Zaak D *et al*. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. *Cancer Res* 2002;**62**:809–18.

125. Spruck CH, Rideout WM, Olumi AF *et al*. Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage. *Cancer Res* 1993;**53**:1162–66.

126. García-Closas M, Malats N, Silverman D *et al*. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. *Lancet* 2005;**366**:649–59.

127. Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. *Nat Rev Cancer* 2015;**15**:25–41.